Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator Initiated Study Evaluating the Safety, Tolerability, and Efficacy of OTOV101N+OTOV101C Injection in Treating Patients With OTOF Mutation-related Deafness

NCT05901480 is registered in ClinicalTrials.gov with Otovia Therapeutics as lead sponsor.

NCT NCT05901480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05901480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator Initiated Study Evaluating the Safety, Tolerability, and Efficacy of OTOV101N+OTOV101C Injection in Treating Patients With OTOF Mutation-related Deafness
Lead sponsor
Otovia Therapeutics
Phase
Not applicable
Overall status
Unknown status
Start date
June 26, 2023
Completion date
February 18, 2025
Enrollment
25 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

dfnb9